MRK news

Merck & Co. announced Q3 2026 sales of $18.1B with oncology product Keytruda leading growth. The company raised its full-year sales guidance to $66.8B-$67.3B.

Guidance Oct 29, 2026 sentiment +0.60 SEC filing ↗

MRK

Merck & Co Q3 Adj. EPS $2.49 Beats $2.08 Estimate, Sales $18.085B Beat $17.313B Estimate

News Oct 29, 2026 sentiment +0.80 Source: benzinga.com ↗

MRK

Merck Q3 KEYTRUDA/KEYTRUDA QLEX Sales $8.60B (+6% Y/Y)

Earnings Oct 29, 2026 sentiment +0.30 Source: benzinga.com ↗

MRK

Merck & Co Raises FY2026 Adj EPS Guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 Est; Raises FY2026 Sales Guidance from $66.300B-$67.300B to $66.800B-$67.300B vs $67.052B Est

News Oct 29, 2026 sentiment +0.60 Source: benzinga.com ↗

MRK

Merck Expects Underlying Operating Expenses To Increase Mid- To High-Single Digits Next Year; For Keytruda Expecting Moderating Growth As We Approach Peak Revenues For Certain Approved Indications; For Keytruda, Expecting German Market To Be Impacted By Policy Dynamics; Expecting Keytruda & Winrevair Benefit To Fully Unwind In Q4; Majority Of Vaccines Benefit, Primarily Gardasil, To Unwind In 2027

News Oct 29, 2026 sentiment -0.40 Source: benzinga.com ↗

MRK

Merck Exec Says It Expects Moderate Top-Line Growth In 2027

News Oct 29, 2026 sentiment 0.00 Source: benzinga.com ↗

MRK

Merck Exec Says Growth Will Be Partially Offset By More Than $2B Of Headwinds From Generic Competition And LOE; It Now Expects To Raise Forecast Of $70B In Revenue Mid-2030s From New Growth Drivers

News Oct 29, 2026 sentiment -0.30 Source: benzinga.com ↗

MRK

Merck shares are trading higher after reporting better-than-expected Q3 financial results and raising its FY26 guidance above estimates.

WIIM Oct 29, 2026 sentiment +0.80 Source: benzinga.com ↗

MRK

Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027

Trading Ideas Oct 29, 2026 sentiment +0.20 Source: benzinga.com ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same MRK feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/MRK/newsSTART FREE